Nitric Oxide Production in MELAS Syndrome
Recruitment status was Recruiting
Baylor College of Medicine and Texas Children's Hospital are recruiting individuals with MELAS syndrome for a clinical study. Mitochondria are cell structures that provide energy for most cells of the body. MELAS syndrome is a mitochondrial disease; patients with this disease have muscle weakness and often develop brain strokes, where blood does not flow normally to different parts of the brain. It is believed that these strokes could be due to decreased production of nitric oxide, a naturally occurring compound important for normal blood vessel function. Nitric oxide is made from other common compounds arginine and citrulline that are normally found in our bodies.
What is the purpose of this study? The purpose of this study is to measure nitric oxide in individuals with MELAS syndrome and see if giving arginine or citrulline will increase the formation of nitric oxide. Nitric oxide is thought to be helpful in improving blood vessel function and preventing strokes. Therefore, if arginine and/or citrulline are shown to increase the formation of nitric oxide, they could be used to prevent or treat the strokes in patients with MELAS syndrome.
What does the study involve? Individuals with MELAS syndrome will be admitted twice to the General Clinical Research Center (GCRC) at Texas Children's Hospital. Each time they will stay for five days, during which a special diet will be provided. Nitric oxide production will be measured by a safe stable isotopes infusion technique that involves placing small tubes in veins (IV catheter), blood sampling, and injecting a harmless stable isotope. Stable isotopes are forms of normal compounds that can be measured very accurately but not radioactive and there are no known risks to giving them; they are already part of your body in small amounts.
During the first admission nitric oxide levels will be measured, then arginine supplementation will be provided for 48 hours, after which nitric oxide levels will be re-measured to determine the effect of arginine supplementation. During the second admission, the effect of citrulline supplementation will be measured.
Who can participate in the study? Adults or children affected with MELAS syndrome and carrying the DNA change that causes the condition (3243 A>G mutation) can participate. Adults without MELAS disease will be recruited to participate as control subjects.
How to get more information? Subjects interested in participation or getting more information can contact Dr. Ayman El-Hattab at email: firstname.lastname@example.org, office phone: 832-822-4289, cell phone: 646-660-5666, or pager: 832-824-7243 (5523).
|Study Design:||Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||ARGININE FLUX AND NITRIC OXIDE PRODUCTION IN PATIENTS WITH MELAS SYNDROME AND THE EFFECT OF ARGININE AND CITRULLINE SUPPLEMENTATION|
- Change in nitric oxide production [ Time Frame: Nitric oxide production will be measured at baseline before supplementation and after 48 hours of arginine or citrulline supplementation ] [ Designated as safety issue: No ]
|Study Start Date:||July 2009|
|Estimated Primary Completion Date:||June 2012 (Final data collection date for primary outcome measure)|
Dietary Supplement: Arginine and citrulline supplementations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01339494
|Contact: Ayman W El-Hattab, M.D.||email@example.com|
|United States, Texas|
|Texas Children's Hospital||Recruiting|
|Houston, Texas, United States, 77030|
|Contact: Ayman W El-Hattab, MD 832-822-4289 firstname.lastname@example.org|
|Principal Investigator: Fernando Scaglia, MD|
|Principal Investigator:||Fernando Scaglia, M.D.||Baylor College of Medicine|